Deal Timeline

Plotted by close date where disclosed, otherwise announcement. Select any marker to jump to the deal entry.

$41.8M
Aug 2020
CartaNA AB
$407.4M
Oct 2020
ReadCoor
$8.5M
Jan 2021
Tetramer Shop ApS

The Rationale That Repeats.

Three patterns show up across 10x Genomics's deal book — what the team buys, how it pays, and how it integrates. The patterns are the throughline; the deals below are the evidence.

01
Acquisition criteria
Acquire the foundational technology, then turn it into a product platform.
Every 10x Genomics acquisition brought in foundational IP that became the basis of a named product line: Epinomics' ATAC-seq fed the Chromium Single Cell ATAC Solution, Spatial Transcriptomics became Visium, and ReadCoor plus CartaNA together formed the foundation of the Xenium In Situ platform. The deals were technology and IP buys, not revenue or distribution plays.
CartaNA ABReadCoorTetramer Shop ApS
02
Capital deployment
Buy out competing approaches to lock up an emerging field.
In the In Situ space, 10x acquired both ReadCoor (a Harvard spinout from George Church's lab) and CartaNA (out of Mats Nilsson's lab at Stockholm University) within the same announcement, combining more than 110 In Situ patents and applications. Management framed both deals as the result of a comprehensive assessment of In Situ efforts worldwide — consolidating the strongest teams and IP rather than competing against them.
CartaNA ABReadCoorTetramer Shop ApS
03
Integration approach
A strong Scandinavian R&D footprint.
Three of the five targets were Northern European — Spatial Transcriptomics and CartaNA in Stockholm and Tetramer Shop in Copenhagen — and the acquired teams were folded into 10x's Swedish research center. The pattern reflects 10x sourcing deep academic expertise in spatial and in situ biology directly from the European labs that pioneered those methods.
CartaNA ABReadCoorTetramer Shop ApS

The Full Deal Book

3 acquisitions. Each entry carries the deal value, financing structure, target revenue, executive commentary, and the original SEC filing — the evidence behind the patterns above.

01 CartaNA AB · Stockholm, Sweden $41.8M
Announced Oct 2020• Closed Aug 2020 •Acquisition of all outstanding shares; total $41.8M inclusive of $0.6M transaction costs and net of $1.5M cash acquired
In Situ RNA analysis technology and a suite of proprietary reagents enabling visualization of spatially resolved RNA expression at sub-cellular resolution within tissue sections

Acquisition of Stockholm-based CartaNA AB, a developer of In Situ RNA analysis technology that came out of Mats Nilsson's SciLifeLab at Stockholm University. The acquisition closed August 21, 2020 and was disclosed alongside the ReadCoor agreement on October 5, 2020.

After a comprehensive assessment of In Situ efforts worldwide, we are thrilled to welcome ReadCoor and CartaNA to the 10x team. Both companies have made significant technical advances, which will serve as a powerful foundation for future product development at 10x.Serge Saxonov — co-founder and CEO of 10x Genomics
Our team has been focused on developing In Situ technologies for a number of years, starting with work at Stockholm University and Karolinska Institute. We are thrilled to join 10x and become a part of their Swedish research center in Stockholm.Malte Kuhnemund — co-founder and EVP of R&D at CartaNA
02 ReadCoor, Inc. · Cambridge, Massachusetts, United States $407.4M
Announced Oct 2020• Closed Oct 2020 •Cash-and-stock merger; total consideration $407.4M comprising $101.4M cash and $306.0M in stock
Foundational In Situ technologies and proprietary reagents enabling visualization of spatially resolved RNA expression at sub-cellular resolution in fresh-frozen or FFPE tissue sectionsover 110 In Situ patents and applications combined with CartaNA

Acquisition of Cambridge, MA-based ReadCoor, Inc., a developer of foundational In Situ RNA analysis technology spun out of George Church's lab at Harvard. Announced October 5, 2020 for cash and stock consideration of $350 million and completed October 13, 2020.

We believe that In Situ approaches will be essential for how biological research and clinical assays will be conducted in the future. After a comprehensive assessment of In Situ efforts worldwide, we are thrilled to welcome ReadCoor and CartaNA to the 10x team.Serge Saxonov — co-founder and CEO of 10x Genomics
We have followed and been impressed with 10x Genomics for years and look forward to combining forces as we execute on a shared vision.Richard Terry — founder and CEO of ReadCoor
03 Tetramer Shop ApS · Copenhagen, Denmark $8.5M
Announced Feb 2021• Closed Jan 2021 •All-cash acquisition of 100% of outstanding shares; total cash consideration $8.5M net of $0.2M cash acquired, including $1.5M contingent consideration
Expertise in building emptyloadable major histocompatibility complex (MHC) molecules used for precise monitoring of antigen-specific T cells

Acquisition of Copenhagen, Denmark-based Tetramer Shop ApS, a life sciences technology company that developed and provided reagents for precise monitoring of antigen-specific T cells in research and development. The acquisition closed January 8, 2021 and was announced publicly at 10x's inaugural Xperience event on February 24, 2021.

We had a solid start to the year highlighted by strong growth across the business and the incredible response to the innovation revealed at our inaugural Xperience event.Serge Saxonov — Co-founder and CEO of 10x Genomics

More Acquirer Playbooks

Acquisition history

CHEMED CORP
Acquisition history

CLOROX CO /DE/
Acquisition history

PPL Corp

See how VectorShift works for your firm

Request Demo